Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period

Clinical Therapeutics

Volumn 36, Issue 1, 2014, Pages 70-83

  Schiller, Brigitte ^a   Bhat, Premila ^b   Sharma, Amit ^c  

^a University of Minnesota   (United States)

^b Aero Nav Laboratories   (United States)

^c Pacific Renal Research Institute   (United States)

Author keywords

chronic kidney disease; ferumoxytol; hemodialysis; intravenous iron; iron deficiency anemia

Indexed keywords

FERRITIN; FERUMOXYTOL; HEMOGLOBIN; TRANSFERRIN;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DYSPNEA; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INJECTION; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRURITUS; RENAL REPLACEMENT THERAPY-DEPENDENT RENAL DISEASE; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL; UNITED STATES; VOMITING;

CHRONIC KIDNEY DISEASE; FERUMOXYTOL; HEMODIALYSIS; INTRAVENOUS IRON; IRON-DEFICIENCY ANEMIA;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERROSOFERRIC OXIDE; HEMATINICS; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84892372224     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.028     Document Type: Article

References (35)

1. R.J. Schmidt, and C.L. Dalton Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations Osteopath Med Prim Care 1 2007 14
2. S. Nurko Anemia in chronic kidney disease: causes, diagnosis, treatment Cleve Clin J Med 73 2006 289 297
3. Kumar P, Clark M, eds. Pocket Essentials of Clinical Medicine. 4th ed. Saunders Elsevier Limited: Amsterdam; 2007.
4. I.C. Macdougall Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 26 2010 473 482
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO Clinical Practice Guideline for Anemia in CKD Kidney Int Suppl 2 2012 279 335
6. National Kidney Foundation Disease Outcomes Quality Initiative (NKF-KDOQI) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease Am J Kidney Dis 47 2006 S11 S145
7. EBPG II Working Group Treatment of renal anaemia Nephrol Dial Transplant 19 2004 ii16 ii31
8. J. Albaramki, E.M. Hodson, J.C. Craig, and A.C. Webster Parenteral versus oral iron therapy for adults and children with chronic kidney disease Cochrane Database Syst Rev 1 2012 CD007857
9. Ferinject [summary of product information] Neuilly-sur-Seine 2011 Vifor France SA France
10. Cosmofer [summary of product information] Holbaek 2012 Pharmacosmos A/S Denmark
11. Venofer [summary of product information] Neuilly-sur-Seine 2011 Vifor France SA France
12. Ferrlecit [summary of product information] Frankfurt am Main 2009 Sanofi-Aventis Deutschland GmbH Germany
13. Monofer [summary of product information] Holbaek 2013 Pharmacosmos A/S Denmark
14. W.Y. Qunibi The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review Arzneimittelforschung 60 2010 399 412
15. D.B. Van Wyck, M. Roppolo, and C.O. Martinez et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD Kidney Int 68 2005 2846 2856
16. I.C. Macdougall, and A. Roche Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections Am J Kidney Dis 46 2005 283 289
17. S. Prakash, A. Walele, and N. Dimkovic et al. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients Perit Dial Int 21 2001 290 295
18. K. Bishu, and R. Agarwal Acute injury with intravenous iron and concerns regarding long-term safety Clin J Am Soc Nephrol 1 Suppl 1 2006 S19 S23
19. D. Gozzard When is high-dose intravenous iron repletion needed? Assessing new treatment options Drug Des Devel Ther 5 2011 51 60
20. V.S. Balakrishnan, M. Rao, and A.T. Kausz et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation Eur J Clin Invest 39 2009 489 496
21. M.H. Rosner, and M. Auerbach Ferumoxytol for the treatment of iron deficiency Expert Rev Hematol 4 2011 399 406
22. Rienso [summary of product information] Aldwych 2012 Takeda Global Research and Development Centre (Europe) Ltd London, United Kingdom
23. B.S. Spinowitz, A.T. Kausz, and J. Baptista et al. Ferumoxytol for treating iron deficiency anemia in CKD J Am Soc Nephrol 19 2008 1599 1605
24. P.L. McCormack Ferumoxytol in iron deficiency anaemia in adults with chronic kidney disease Drugs 72 2012 2013 2022
25. R. Provenzano, B. Schiller, and M. Rao et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients Clin J Am Soc Nephrol 4 2009 386 393
26. Macdougall IC, McLaughlin J, Fortin GS, et al. The FIRST head to head comparison study (Ferumoxytol Compared With Iron Sucrose Trial) for the treatment of iron deficiency anemia in patients with chronic kidney disease. Poster presented at: American Society of Nephrology Kidney Week 2011; November 8-13, 2011; Philadelphia, Pa.
27. A. Singh, T. Patel, and J. Hertel et al. Safety of ferumoxytol in patients with anemia and CKD Am J Kidney Dis 52 2008 907 915
28. S. Bhandari Beyond efficacy and safety - the need for convenient and cost-effective iron therapy in health care NDT Plus 4 2011 i14 i19
29. G.R. Bailie Comparison of rates of reported adverse events associated with i.v. iron products in the United States Am J Health Syst Pharm 69 2012 310 320
30. M. Auerbach, and R.C. Kane Caution in making inferences from FDA's Adverse Event Reporting System Am J Health Syst Pharm 69 2012 922 923
31. Feraheme [prescribing information]. Lexington, Mass: AMAG Pharmaceuticals; 2011.
32. J. Ring, K. Brockow, and H. Behrendt History and classification of anaphylaxis Novartis Found Symp 257 2004 6 16
33. G. Anirban, H.S. Kohli, and V. Jha et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients Ren Fail 30 2008 629 638
34. US Renal Data System USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2012 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, Md
35. R. Vanholder, A. Davenport, and T. Hannedouche et al. Reimbursement of dialysis: a comparison of seven countries J Am Soc Nephrol 23 2012 1291 1298